Posted by Michael Wonder on 28 Feb 2019
Janssen announces U.S. FDA approval of novel Tremfya (guselkumab) one-press patient-controlled injector for adults with moderate-to-severe plaque psoriasis
27 February 2019 - Nearly 99% of patients using One-Press for the first time completed a successful injection.
Janssen today announced that the U.S. FDA has approved Tremfya One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. Temfya (guselkumab) is the first FDA-approved medication of its kind to offer the One-Press patient-controlled injector. One-Press was designed with patients in mind: it fits comfortably in the hand and offers a controlled injection that hides the needle throughout the process.
Tremfya is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4.
